Hospitals sue Trump administration over 340B drug discount rebate pilot

The American Hospital Association and safety-net hospital groups sued HHS on October 9, 2026, to block a Trump administration pilot converting 340B upfront drug discounts into post-purchase rebates for 25 costly Medicare drugs starting January 1, 2027. Plaintiffs argue administrative expenses could exceed $1 billion annually, overburdening safety-net providers operating on thin margins, while drugmakers contend the 340B program's $100 billion footprint reflects growing hospital profiteering.

Lawsuit challenging the rebate pilot

• ▪The American Hospital Association's lawsuit against HHS alleges that HRSA received over 2,400 public comments detailing the operational burdens and potential patient care disruptions created by the 340B rebate model
• ▪The American Hospital Association, the Maine Hospital Association, and four safety-net hospitals filed a lawsuit against HHS in Maine district court on October 9, 2026, seeking to halt a 340B drug discount rebate pilot set to begin January 1, 2027

Financial impact on hospitals

• ▪Hospital plaintiffs argue the 340B rebate program would force thin-margin safety-net providers to dip into cash reserves to buy drugs upfront while facing Medicaid spending cuts and inflationary pressures
• ▪HRSA estimated the 340B rebate pilot, set to take effect January 1, 2027, would cost $537 million annually, but hospital plaintiffs allege annual administrative costs could surpass $1 billion due to startup, technology, and reconciliation expenses

Details of the revamped pilot

• ▪HRSA's revamped 340B rebate pilot would convert upfront drug discounts into post-purchase rebates targeting 25 of the costliest and most widely used Medicare drugs starting January 1, 2027
• ▪HRSA expanded its refreshed 340B rebate pilot in 2026 to include 25 costliest Medicare drugs, up from 10 drugs included in its initial 2025 proposal

Debatable claims

• ▪Expanding 340B drug purchases is driven by hospital financial gain rather than patient need
• ▪HHS should abandon its plan to replace 340B upfront discounts with rebates